Drug recall · May 6, 2020
Nizatidine Oral Solution recall
Why: CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) USP 480 mL bottles, Rx Only Distributed by: Gemini Laboratories, LLC Bridgewater, NJ 08807 NDC 60846-301-15
- Lots / codes
06598004A 04/2020 06599001A 12/2020 06599002A 12/2020
- Quantity
- 11258 bottles
- Company
- Amneal Pharmaceuticals of New York, LLC, Brookhaven, NY
- Distribution
- Nationwide
- Initiated
- April 15, 2020 · Voluntary: Firm initiated
- Classified
- April 24, 2020
- Reported
- May 6, 2020
- Ended
- September 8, 2021
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nizatidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.